Conditions: Human Immunodeficiency Virus Infection
Keywords: Human Immunodeficiency Virus infection
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 206
Healthy volunteers: no

Brief summary:
The purpose of this study is to compare the safety, tolerability, and antiviral activity of the lopinavir/ritonavir tablet when administered in combination with reverse transcriptase inhibitors to lopinavir/ritonavir tablets when administered in combination with a human immunodeficiency virus type 1 ( HIV-1) integrase inhibitor in antiretroviral naive HIV-1 infected subjects.

Detailed description:

Arms:
arm 1: lopinavir/ritonavir 400/100 milligram (mg) tablet twice-daily + co-formulated emtricitabine/tenofovir disoproxil fumarate 200/300 mg once-daily arm 2: lopinavir/ritonavir 400/100 mg tablet twice-daily + raltegravir 400 mg twice-daily

Interventions: intervention 1: lopinavir/ritonavir (LPV/r) intervention 2: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) intervention 3: raltegravir (RAL)
Intervention descriptions: intervention 1: LPV/r 400/100 mg BID intervention 2: FTC/TDF 200/300 mg QD intervention 3: RAL 400 mg BID

Protocol document: